5,421
edits
(Created page with "== Haemostasis == Haemostasis is the body’s response to stop bleedings after endothelial damage. It consists of three steps: * Primary haemostasis ** Local vasoconstriction ** Platelet plug formation * Secondary haemostasis ** Clot formation * Fibrinolysis ** Dissolving the blood clot === Coagulation factors === Most of the components involved in haemostasis are found in the blood. The first are the platelets. The second are the coagulation factors. The coagulation f...") |
No edit summary |
||
Line 1: | Line 1: | ||
Haemostasis is the body’s response to stop bleedings after endothelial damage. It consists of three steps: | Haemostasis is the body’s response to stop bleedings after endothelial damage. It consists of three steps: | ||
Line 10: | Line 9: | ||
** Dissolving the blood clot | ** Dissolving the blood clot | ||
== Coagulation factors == | |||
Most of the components involved in haemostasis are found in the blood. The first are the platelets. The second are the coagulation factors. The coagulation factors are proteins in the plasma that are involved in haemostasis. There are many coagulation factors. They travel in the blood in an inactive state. Most of them have two names, one which is just a roman numeral, and one which is their real name. Some coagulation factors are referred to by their roman number and some are referred to by their real name. Almost all of them are synthesized in the liver. | Most of the components involved in haemostasis are found in the blood. The first are the platelets. The second are the coagulation factors. The coagulation factors are proteins in the plasma that are involved in haemostasis. There are many coagulation factors. They travel in the blood in an inactive state. Most of them have two names, one which is just a roman numeral, and one which is their real name. Some coagulation factors are referred to by their roman number and some are referred to by their real name. Almost all of them are synthesized in the liver. | ||
{| class="wikitable" | {| class="wikitable" | ||
!'''Factor''' | |||
!'''Real name''' | |||
!'''Vitamin K required for synthesis''' | |||
|- | |- | ||
|I | |I | ||
Line 97: | Line 96: | ||
''A protein in an inactive state is usually given an “-ogen” suffix. As an example, the inactive form of plasmin is plasminogen, and the inactive form of fibrin is fibrinogen.'' | ''A protein in an inactive state is usually given an “-ogen” suffix. As an example, the inactive form of plasmin is plasminogen, and the inactive form of fibrin is fibrinogen.'' | ||
== Primary haemostasis == | |||
When there is endothelial damage the first priority is to “plug” the hole. This is the goal of primary haemostasis. | When there is endothelial damage the first priority is to “plug” the hole. This is the goal of primary haemostasis. | ||
=== Vasoconstriction === | |||
The first component of primary haemostasis is ''vasoconstriction'', the contraction of the smooth muscle in the wall of the broken vessel. This shrinks the lumen of the vessel, which decreases the blood flow through it. This makes it much easier for the plug to form and it decreases the amount of blood lost. This vasoconstriction is mediated by a local nervous pain reflex, and by the local release of vasoconstricting proteins. | The first component of primary haemostasis is ''vasoconstriction'', the contraction of the smooth muscle in the wall of the broken vessel. This shrinks the lumen of the vessel, which decreases the blood flow through it. This makes it much easier for the plug to form and it decreases the amount of blood lost. This vasoconstriction is mediated by a local nervous pain reflex, and by the local release of vasoconstricting proteins like endothelin, one of the strongest vasoconstrictors. | ||
=== Platelet plug formation === | |||
The second component of primary haemostasis is the platelet plug formation. | The second component of primary haemostasis is the platelet plug formation. Formation of this plug requires platelet adherence, followed by platelet activation, then lastly by platelet aggregation. | ||
These granules contain many compounds, like serotonin, ADP and thromboxane A2. These compounds further stimulate vasoconstriction of the vessel, and they stimulate other platelets nearby to become activated as well. All activated platelets bind to and stick to the damaged endothelium and to each other, and | When the endothelium of a vessel is damaged the blood will be exposed to the proteins that lie beneath the endothelium, especially collagen, which is abundant in the interstitium. Platelets in the blood recognize and ''adhere'' strongly to the collagen using the ''glycoprotein Ia/IIb'' receptor, both directly and with the help of von Willebrand factor (vWF). von Willebrand factor is released by injured endothelial cells and binds to exposed collagen, serving as binding sites for the platelet ''glycoprotein Ib'' receptor to bind to. | ||
The adherence of platelets to collagen ''activates'' the platelets, causing them to release the content of their granules into the surrounding blood. These granules contain many compounds, like serotonin, vWF, ADP and thromboxane A2. These compounds further stimulate vasoconstriction of the vessel, and they stimulate other platelets nearby to become activated as well. ADP binds to receptors P2Y1 and P2Y12 to mediate these effects. | |||
All activated platelets bind to and stick to the damaged endothelium and to each other, a process called ''aggregation''. Platelets adhere to each other by binding the platelet surface receptor GPIb/IX/V complex to von Willebrand factor (VWF) in the subendothelial matrix, and by binding to fibrinogen using the glycoprotein IIb/IIIa receptor on the platelet surface. Their activation causes them to change shape from round to a star-like shape. This change in shape makes it easier for the platelets to aggregate and form a ''platelet plug'', also called a ''white plug''. | |||
This platelet plug isn’t very stable; it can loosen easily. To ensure that the platelet plug is stable enough to remain until the endothelial damage has been repaired, we must “secure” the plug in place. This is where secondary haemostasis comes in. | This platelet plug isn’t very stable; it can loosen easily. To ensure that the platelet plug is stable enough to remain until the endothelial damage has been repaired, we must “secure” the plug in place. This is where secondary haemostasis comes in. | ||
== Secondary haemostasis == | |||
Secondary haemostasis is the process of stabilizing the platelet plug by forming a mesh of a protein called ''fibrin''. This process is complicated. | Secondary haemostasis is the process of stabilizing the platelet plug by forming a mesh of a protein called ''fibrin''. This process is complicated. | ||
Line 117: | Line 120: | ||
The coagulation cascade is (somewhat arbitrarily) divided into two main pathways; the extrinsic pathway and the intrinsic pathway, both of which end in the ''common'' pathway. The final point of the extrinsic and intrinsic pathways is the activated factor X, which is also the beginning of the common pathway. | The coagulation cascade is (somewhat arbitrarily) divided into two main pathways; the extrinsic pathway and the intrinsic pathway, both of which end in the ''common'' pathway. The final point of the extrinsic and intrinsic pathways is the activated factor X, which is also the beginning of the common pathway. | ||
=== Intrinsic pathway === | |||
The intrinsic pathway, also called the ''contact activation pathway'' begins when the blood touches a negatively charged surface, such as collagen or glass. Glass is obviously not present in the body, but collagen is a major component of subendothelial tissues. As such, when endothelium is damaged, the blood is exposed to collagen, and so the intrinsic pathway initiates. | The intrinsic pathway, also called the ''contact activation pathway'' begins when the blood touches a negatively charged surface, such as collagen or glass. Glass is obviously not present in the body, but collagen is a major component of subendothelial tissues. As such, when endothelium is damaged, the blood is exposed to collagen, and so the intrinsic pathway initiates. | ||
When blood touches the collagen or glass factor XII will be activated, turning into its activated form XIIa. Activated factor XII (XIIa) will activate factor XI. Activated factor XI (XIa) will activate factor IX. Activated factor IX (IXa) will, together with factor VIII activate factor X. | When blood touches the collagen or glass factor XII will be activated, turning into its activated form XIIa. Activated factor XII (XIIa) will activate factor XI. Activated factor XI (XIa) will activate factor IX. Activated factor IX (IXa) will, together with factor VIII activate factor X. | ||
=== Extrinsic pathway === | |||
A protein called ''tissue factor'' (TF) is also present in subendothelial tissue. When the endothelium of a vessel is damaged the underlying TF will be exposed to blood, which initiates the extrinsic pathway. Factor VII will bind to tissue factor and become activated. VIIa activates factor IX and factor X. | A protein called ''tissue factor'' (TF) is also present in subendothelial tissue. When the endothelium of a vessel is damaged the underlying TF will be exposed to blood, which initiates the extrinsic pathway. Factor VII will bind to tissue factor and become activated. VIIa activates factor IX and factor X. | ||
=== Common pathway === | |||
Activated factor X (Xa) will activate factor II, converting it from prothrombin to thrombin. Thrombin will activate factor I, converting it from fibrinogen to fibrin. Thrombin also activates factor XIII. | Activated factor X (Xa) will activate factor II, converting it from prothrombin to thrombin. Thrombin will activate factor I, converting it from fibrinogen to fibrin. Thrombin also activates factor XIII. | ||
Line 132: | Line 135: | ||
''The coagulation system is described as divided into the intrinsic and extrinsic pathways as a result of how the coagulation cascade acts in the laboratory (in vitro), not in the body (in vivo). The intrinsic pathway is initiated when blood comes in contact with glass, and the pathway was described according to what happened to the blood after this contact. The extrinsic pathway is initiated when blood comes in contact with thromboplastin, a mixture of tissue factor and phospholipids.The model depicted here is old and outdated; we now know that the two systems are not redundant in vivo but are both needed. In the body, tissue damage initiates the extrinsic pathway, which generates a small amount of thrombin but also activates the "intrinsic" pathway, which in turn generates a lot of thrombin. Also, deficiency of some factors in the intrinsic pathway doesn’t cause a defect in haemostasis (but rather in immunity).'' | ''The coagulation system is described as divided into the intrinsic and extrinsic pathways as a result of how the coagulation cascade acts in the laboratory (in vitro), not in the body (in vivo). The intrinsic pathway is initiated when blood comes in contact with glass, and the pathway was described according to what happened to the blood after this contact. The extrinsic pathway is initiated when blood comes in contact with thromboplastin, a mixture of tissue factor and phospholipids.The model depicted here is old and outdated; we now know that the two systems are not redundant in vivo but are both needed. In the body, tissue damage initiates the extrinsic pathway, which generates a small amount of thrombin but also activates the "intrinsic" pathway, which in turn generates a lot of thrombin. Also, deficiency of some factors in the intrinsic pathway doesn’t cause a defect in haemostasis (but rather in immunity).'' | ||
== Fibrinolysis == | |||
Fibrinolysis is the process where the blood clot is broken down. This process is activated simultaneously as the coagulation cascade, and both processes occur simultaneously. This is to prevent the blood clot from growing too large and occluding the whole blood vessel. Fibrinolysis is also involved in removing the blood clot completely after the damage to the blood vessel has been repaired. | Fibrinolysis is the process where the blood clot is broken down. This process is activated simultaneously as the coagulation cascade, and both processes occur simultaneously. This is to prevent the blood clot from growing too large and occluding the whole blood vessel. Fibrinolysis is also involved in removing the blood clot completely after the damage to the blood vessel has been repaired. | ||
Line 147: | Line 150: | ||
The formed blood clot contains a lot of plasminogen. A few days after the blood clot has been formed and the bleeding has stopped will the endothelium secrete tissue plasminogen activator. This protein activates the plasminogen, which is contained in the blood clot, converting it into plasmin. Plasmin then dissolves the clot. | The formed blood clot contains a lot of plasminogen. A few days after the blood clot has been formed and the bleeding has stopped will the endothelium secrete tissue plasminogen activator. This protein activates the plasminogen, which is contained in the blood clot, converting it into plasmin. Plasmin then dissolves the clot. | ||
== Organisation == | |||
In some cases, the blood clots aren’t broken down by fibrinolysis but instead ''organized''. This means that they’re slowly replaced by connective tissue formed by a type of cell called the ''fibroblast''. | In some cases, the blood clots aren’t broken down by fibrinolysis but instead ''organized''. This means that they’re slowly replaced by connective tissue formed by a type of cell called the ''fibroblast''. | ||
== Anticoagulation == | |||
The body is constantly in a balance between procoagulation and anticoagulation. Both of these processes occur simultaneously and in a balance, so that neither too many (or too large) nor too few blood clots are formed. The term ''thrombosis'' refers to when a blood clot is too large and completely obstructs a blood vessel. This can be very dangerous and is the basis of heart attacks and strokes, among other diseases. | The body is constantly in a balance between procoagulation and anticoagulation. Both of these processes occur simultaneously and in a balance, so that neither too many (or too large) nor too few blood clots are formed. The term ''thrombosis'' refers to when a blood clot is too large and completely obstructs a blood vessel. This can be very dangerous and is the basis of heart attacks and strokes, among other diseases. | ||
Line 166: | Line 169: | ||
Coumarins are used to treat people who are at risk for ''thrombosis''. | Coumarins are used to treat people who are at risk for ''thrombosis''. | ||
== Coagulation tests == | |||
There are multiple tests we can perform on the blood to determine the function of the different parts of haemostasis. | There are multiple tests we can perform on the blood to determine the function of the different parts of haemostasis. | ||
Line 177: | Line 180: | ||
The problem with prothrombin time is that the result varies significantly from lab to lab, depending on equipment and substrates used. To overcome this the result of the measurement needs to be normalized. This is done by inserting the prothrombin time into an equation, which gives you the ''international normalized ratio'' (INR). The INR is therefore a measurement of the prothrombin time, but it is standardized so that differences between laboratories doesn’t influence the result. | The problem with prothrombin time is that the result varies significantly from lab to lab, depending on equipment and substrates used. To overcome this the result of the measurement needs to be normalized. This is done by inserting the prothrombin time into an equation, which gives you the ''international normalized ratio'' (INR). The INR is therefore a measurement of the prothrombin time, but it is standardized so that differences between laboratories doesn’t influence the result. | ||
{| class="wikitable" | {| class="wikitable" | ||
!'''Parameter''' | |||
!'''Function examined''' | |||
!'''Normal range''' | |||
!'''Elevated result in''' | |||
|- | |- | ||
|Bleeding time | |Bleeding time | ||
Line 203: | Line 206: | ||
|} | |} | ||
== Diseases of haemostasis == | |||
Many diseases of haemostasis exist, both congenital and acquired. Here are the most important ones and which parameter they affect: | Many diseases of haemostasis exist, both congenital and acquired. Here are the most important ones and which parameter they affect: | ||
{| class="wikitable" | {| class="wikitable" | ||
!'''Disease''' | |||
!'''Pathological background''' | |||
!'''Pathway affected''' | |||
!'''Abnormal parameter''' | |||
|- | |- | ||
|Thrombocytopaenia | |Thrombocytopaenia |